Nanotechnology-based drug delivery systems for the treatment of Alzheimer’s disease

References

• DuboisBFeldmanHHJacovaCRevising the definition of Alzheimer’s disease: a new lexiconLancet Neurol20109111118112720934914
   PubMed Web of Science ®Google Scholar
• QuerfurthHWLaFerlaFMAlzheimer’s diseaseN Engl J Med2010362432934420107219
   PubMed Web of Science ®Google Scholar
• Alzheimer’s Association2013 Alzheimer’s disease facts and figuresAlzheimers Dement20139220824523507120
   PubMed Web of Science ®Google Scholar
• SoodSJainKGowthamarajanKIntranasal therapeutic strategies for management of Alzheimer’s diseaseJ Drug Target201422427929424404923
   PubMed Web of Science ®Google Scholar
• MehtaMAdemASabbaghMNew acetylcholinesterase inhibitors for Alzheimer’s diseaseInt J Alzheimers Dis2012201272898322216416
   PubMedGoogle Scholar
• ColovićMBKrstićDZLazarević-PaštiTDBondžićAMVasićVMAcetylcholinesterase inhibitors: pharmacology and toxicologyCurr Neuropharmacol201311331533524179466
   PubMed Web of Science ®Google Scholar
• JannMWShirleyKLSmallGWClinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitorsClin Pharmacokinet2002411071973912162759
   PubMed Web of Science ®Google Scholar
• WatkinsPBZimmermanHJKnappMJGraconSILewisKWHepa-totoxic effects of tacrine administration in patients with Alzheimer’s diseaseJAMA1994271139929988139084
   PubMed Web of Science ®Google Scholar
• RainaPSantaguidaPIsmailaAEffectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guidelineAnn Intern Med2008148537939718316756
   PubMed Web of Science ®Google Scholar
• PericlouAVenturaDRaoNAbramowitzWPharmacokinetic study of memantine in healthy and renally impaired subjectsClin Pharmacol Ther200679113414316413248
   PubMed Web of Science ®Google Scholar
• KornhuberJKennepohlEMBleichSMemantine pharmacotherapy: a naturalistic study using a population pharmacokinetic approachClin Pharmacokinet200746759961217596105
   PubMed Web of Science ®Google Scholar
• AriasJLKey aspects in nanotechnology and drug deliveryNanotechnology and Drug Delivery. Volume 1: Nanoplatforms in Drug DeliveryBoca RatonCRC Press2015127
   Google Scholar
• SharmaSSinghANanotechnology based targeted drug delivery: current status and future prospects for drug development, drug discovery and developmentKapetanovićIMDrug Discovery and Development: Present and FutureCroatiaInTech2011427462
   Google Scholar
• SuriKWolframJShenHFerrariMAdvances in nanotechnology-based drug delivery platforms and novel drug delivery systemsSinghMSalnikovaMNovel Approaches and Strategies for Biologics, Vaccines and Cancer TherapiesSan DiegoAcademic Press20154158
   Google Scholar
• ParveenSSahooSNanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugsClin Pharmacokinet2006451096598816984211
   PubMed Web of Science ®Google Scholar
• OriveGHernándezRMRodríguez GascónADomínguez-GilAPedrazJLDrug delivery in biotechnology: present and futureCurr Opin Biotechnol200314665966414662398
   PubMed Web of Science ®Google Scholar
• SafariJZarnegarZAdvanced drug delivery systems: nanotechnology of health design A reviewJournal of Saudi Chemical Society20141828599
   Web of Science ®Google Scholar
• BetancourtTDoironAHomanKABrannon-PeppasLControlled release and nanotechnologyde VilliersMMAramwitPKwonGSNanotechnology in Drug DeliveryNew YorkSpringer2009283312
   Google Scholar
• BrambillaDLe DroumaguetBNicolasJNanotechnologies for Alzheimer’s disease: diagnosis, therapy, and safety issuesNanomedicine20117552154021477665
   PubMed Web of Science ®Google Scholar
• NazemAMansooriGANanotechnology solutions for Alzheimer’s disease: advances in research tools, diagnostic methods and therapeutic agentsJ Alzheimers Dis200813219922318376062
   PubMed Web of Science ®Google Scholar
• WilsonBSamantaMKSanthiKKumarKPParamakrishnanNSureshBTargeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticlesEur J Pharm Biopharm2008701758418472255
   PubMed Web of Science ®Google Scholar
• WilsonBSamantaMKSanthiKKumarKPParamakrishnanNSureshBPoly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer’s diseaseBrain Res2008120015916818291351
   PubMed Web of Science ®Google Scholar
• ZhangCWanXZhengXDual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer’s disease miceBiomaterials201435145646524099709
   PubMed Web of Science ®Google Scholar
• ZhangCChenJFengCIntranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer’s diseaseInt J Pharm20144611–219220224300213
   PubMedGoogle Scholar
• BrambillaDVerpillotRDe KimpeLTavernaMLe DroumaguetBAndrieuxKNanoparticles against Alzheimer’s disease: PEG-PACA nanoparticles are able to link the Aβ-peptide and influence its aggregation kineticJ Biotechnol2010150Suppl27
   Google Scholar
• BrambillaDVerpillotRTavernaMNew method based on capillary electrophoresis with laser-induced fluorescence detection (CE-LIF) to monitor interaction between nanoparticles and the amyloid-β peptideAnal Chem20108224100831008921086977
   PubMed Web of Science ®Google Scholar
• JoshiSAChavhanSSSawantKKRivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studiesEur J Pharm Biopharm201076218919920637869
   PubMed Web of Science ®Google Scholar
• FazilMMdSHaqueSDevelopment and evaluation of rivastigmine loaded chitosan nanoparticles for brain targetingEur J Pharm Sci201247161522561106
   PubMed Web of Science ®Google Scholar
• Amorim CdeMCoutoAGNetzDJde FreitasRABresolinTMAntioxidant idebenone-loaded nanoparticles based on chitosan and N-carboxymethylchitosanNanomedicine20106674575220599528
   PubMed Web of Science ®Google Scholar
• YusufMKhanMKhanRAAhmedBPreparation, characterization, in vivo and biochemical evaluation of brain targeted Piperine solid lipid nanoparticles in an experimentally induced Alzheimer’s disease modelJ Drug Target2013213300311
   PubMed Web of Science ®Google Scholar
• SoodSJainKGowthamarajanKCurcumin-donepezil–loaded nanostructured lipid carriers for intranasal delivery in an Alzheimer’s disease modelAlzheimers Dement201394P299
   Google Scholar
• ZhuangCYLiNWangMPreparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailabilityInt J Pharm20103941–217918520471464
   PubMed Web of Science ®Google Scholar
• FrozzaRLSalbegoCBernardiAIncorporation of resveratrol into lipid-core nanocapsules improves its cerebral bioavailability and reduces the Aβ-induced toxicityAlzheimers Dement201174S114
   Google Scholar
• BondìMLCraparoEFGiammonaGDragoFBrain-targeted solid lipid nanoparticles containing riluzole: preparation, characterization and biodistributionNanomedicine (Lond)200951253220025461
   PubMed Web of Science ®Google Scholar
• PatelPAPatilSCKalariaDRKaliaYNPatravaleVBComparative in vitro and in vivo evaluation of lipid based nanocarriers of Huperzine AInt J Pharm20134461–2162323410989
   PubMed Web of Science ®Google Scholar
• KakkarVMuppuSKChopraKKaurIPCurcumin loaded solid lipid nanoparticles: an efficient formulation approach for cerebral ischemic reperfusion injury in ratsEur J Pharm Biopharm2013853 Pt A33934523454202
   PubMed Web of Science ®Google Scholar
• YangZZZhangYQWangZZWuKLouJNQiXREnhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administrationInt J Pharm20134521–234435423680731
   PubMed Web of Science ®Google Scholar
• IsmailMFElmeshadANSalemNAPotential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer’s diseaseInt J Nanomedicine2013839340623378761
   PubMed Web of Science ®Google Scholar
• KumaraswamyPSethuramanSKrishnanUMLiposomal delivery of a beta sheet blocker peptide for the treatment of Alzheimer’s diseaseAlzheimers Dement201284 SupplP705
   Google Scholar
• SanciniGGregoriMSalvatiEFunctionalization with TAT-peptide enhances blood–brain barrier crossing in vitro of nanoliposomes carrying a curcumin-derivative to bind amyloid-β peptideJ Nanomed Nanotechnol201343
   Google Scholar
• MarkoutsaEPapadiaKGiannouADMono and dually decorated nanoliposomes for brain targeting, in vitro and in vivo studiesPharm Res20143151275128924338512
   PubMed Web of Science ®Google Scholar
• MourtasSLazarANMarkoutsaEDuyckaertsCAntimisiarisSGMultifunctional nanoliposomes with curcumin-lipid derivative and brain targeting functionality with potential applications for Alzheimer diseaseEur J Med Chem20148017518324780594
   PubMed Web of Science ®Google Scholar
• LazarANMourtasSYoussefICurcumin-conjugated nanoli-posomes with high affinity for Aβ deposits: possible applications to Alzheimer diseaseNanomedicine20139571272123220328
   PubMed Web of Science ®Google Scholar
• MourtasSCanoviMZonaCCurcumin-decorated nanolipo-somes with very high affinity for amyloid-β1–42 peptideBiomaterials20113261635164521131044
   PubMed Web of Science ®Google Scholar
• MufamadiMSChoonaraYEKumarPLigand-functionalized nanoliposomes for targeted delivery of galantamineInt J Pharm2013448126728123535346
   PubMedGoogle Scholar
• ArumugamKSubramanianGSMallayasamySRAverineniRKReddyMSUdupaNA study of rivastigmine liposomes for delivery into the brain through intranasal routeActa Pharm20088328729719103565
   PubMedGoogle Scholar
• MutluNBDeğimZYılmazŞEşsizDNacarANew perspective for the treatment of Alzheimer diseases: liposomal rivastigmine formulationsDrug Dev Ind Pharm201137777578921231901
   PubMed Web of Science ®Google Scholar
• DegimZMutluNBYilmazSEşsizDNacarAInvestigation of liposome formulation effects on rivastigmine transport through human colonic adenocarcinoma cell line (CACO-2)Pharmazie2010651324020187576
   PubMed Web of Science ®Google Scholar
• RavouruNKondreddyPKorakanchiDHarithaMFormulation and evaluation of niosomal nasal drug delivery system of folic acid for brain targetingCurr Drug Discov Technol201310427028223863098
   PubMedGoogle Scholar
• NaikSRPilgaonkarVWPandaVSEvaluation of antioxidant activity of Ginkgo biloba phytosomes in rat brainPhytother Res200620111013101616909446
   PubMed Web of Science ®Google Scholar
• JinYWenJGargSDevelopment of a novel niosomal system for oral delivery of Ginkgo biloba extractInt J Nanomedicine2013842143023378764
   PubMed Web of Science ®Google Scholar
• ZhangLKXuRXJiangMEvaluation of brain-targeting of β-asarone microemulsion by intranasal administrationChinese Traditional and Herbal Drugs20144518689
   Google Scholar
• ChaiyanaWRadesTOkonogiSCharacterization and in vitro permeation study of microemulsions and liquid crystalline systems containing the anticholinesterase alkaloidal extract from Tabernaemontana divaricataInt J Pharm20134521–220121023680734
   PubMed Web of Science ®Google Scholar
• JoganiVVShahPJMishraPMishraAKMisraARIntranasal mucoadhesive microemulsion of tacrine to improve brain targetingAlzheimer Dis Assoc Disord200822211612418525282
   PubMed Web of Science ®Google Scholar
• SelkoeDJAlzheimer’s disease: genes, proteins, and therapyPhysiol Rev200181274176611274343
   PubMed Web of Science ®Google Scholar
• HardyJSelkoeDJThe amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeuticsScience2002297558035335612130773
   PubMed Web of Science ®Google Scholar
• FinderVHGlockshuberRAmyloid-beta aggregationNeurodegener Dis200741132717429215
   PubMed Web of Science ®Google Scholar
• MattsonMPPathways towards and away from Alzheimer’s diseaseNature2004430700063163915295589
   PubMed Web of Science ®Google Scholar
• BushAIThe metal theory of Alzheimer’s diseaseJ Alzheimers Dis201333Suppl 1S277S28122635102
   PubMed Web of Science ®Google Scholar
• GourasGKBealMFMetal chelator decreases Alzheimer β-amyloid plaquesNeuron200130364164211430794
   PubMed Web of Science ®Google Scholar
• HuangXCuajungcoMPAtwoodCSCu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reductionJ Biol Chem199927452371113711610601271
   PubMed Web of Science ®Google Scholar
• LovellMARobertsonJDTeesdaleWJCampbellJLMarkesberyWRCopper, iron and zinc in Alzheimer’s disease senile plaquesJ Neurol Sci1998158147529667777
   PubMed Web of Science ®Google Scholar
• ChernyRALeggJTMcLeanCAAqueous dissolution of Alzheimer’s disease Abeta amyloid deposits by biometal depletionJ Biol Chem199927433232232322810438495
   PubMed Web of Science ®Google Scholar
• ChernyRAAtwoodCSXilinasMETreatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer’s disease transgenic miceNeuron200130366567611430801
   PubMed Web of Science ®Google Scholar
• BartusRTEmerichDFCholinergic markers in Alzheimer diseaseJAMA1999282232208220910605966
   PubMed Web of Science ®Google Scholar
• RossorMNEmsonPCMountjoyCQRothMIversenLLReduced amounts of immunoreactive somatostatin in the temporal cortex in senile dementia of Alzheimer typeNeurosci Lett19802033733776108540
   PubMed Web of Science ®Google Scholar
• HenkeHLangWCholinergic enzymes in neocortex, hippocampus and basal forebrain of non-neurological and senile dementia of Alzheimer-type patientsBrain Res198326722812916871677
   PubMed Web of Science ®Google Scholar
• SoininenHKosunenOHelisalmiSA severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein epsilon 4 alleleNeurosci Lett1995187279827783963
   PubMed Web of Science ®Google Scholar
• GattazWFForlenzaOVTalibLLBarbosaNRBottinoCMCPlatelet phospholipase A2 activity in Alzheimer’s disease and mild cognitive impairmentJ Neural Transm2004111559160115088152
   PubMed Web of Science ®Google Scholar
• GattazWFTalibLLSchaefferELDinizBSForlenzaOVLow platelet iPLA2 activity predicts conversion from mild cognitive impairment to Alzheimer’s disease: a 4-year follow-up studyJ Neural Transm2014121219320024036895
   PubMed Web of Science ®Google Scholar
• GattazWFCairnsNJLevyRFörstlHBrausDFMarasADecreased phospholipase A2 activity in the brain and in platelets of patients with Alzheimer’s diseaseEur Arch Psychiatry Clin Nuerosci19962463129131
   PubMed Web of Science ®Google Scholar
• WeingartenMDLockwoodAHHwoSYKirschnerMWA protein factor essential for microtubule assemblyProc Natl Acad Sci U S A1975725185818621057175
   PubMed Web of Science ®Google Scholar
• GongCXGrundke-IqbalIIqbalKTargeting tau protein in Alzheimer’s diseaseDrugs Aging201027535136520450234
   PubMed Web of Science ®Google Scholar
• BallatoreCLeeVMTrojanowskiJQTau-mediated neurodegeneration in Alzheimer’s disease and related disordersNat Rev Neurosci20078966367217684513
   PubMed Web of Science ®Google Scholar
• McGeerPLMcGeerEGThe inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseasesBrain Res Brain Res Rev19952121952188866675
   PubMed Web of Science ®Google Scholar
• BlaskoIStampfer-KountchevMRobatscherPVeerhuisREikelenboomPGrubeck-LoebensteinBHow chronic inflammation can affect the brain and support the development of Alzheimer’s disease in old age: the role of microglia and astrocytesAging Cell20043416917615268750
   PubMed Web of Science ®Google Scholar
• MrakREGriffinWSInterleukin-1, neuroinflammation, and Alzheimer’s diseaseNeurobiol Aging200122690390811754997
   PubMed Web of Science ®Google Scholar
• JohnstoneMGearingAJMillerKMA central role for astrocytes in the inflammatory response to beta-amyloid; chemokines, cytokines and reactive oxygen species are producedJ Neuroimmunol1999931–218219310378882
   PubMed Web of Science ®Google Scholar
• TuppoEEAriasHRThe role of inflammation in Alzheimer’s diseaseInt J Biochem Cell Biol200537228930515474976
   PubMed Web of Science ®Google Scholar
• LiCZhaoRGaoKAstrocytes: implications for neuroinflammatory pathogenesis of Alzheimer’s diseaseCurr Alzheimer Res201181678021143158
   PubMed Web of Science ®Google Scholar
• BrownGCBal-PriceAInflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondriaMol Neurobiol200327332535512845153
   PubMed Web of Science ®Google Scholar
• RogersJLueLFMicroglial chemotaxis, activation, and phagocytosis of amyloid beta-peptide as linked phenomena in Alzheimer’s diseaseNeurochem Int2001395–633334011578768
   PubMed Web of Science ®Google Scholar
• SperlingRAAisenPSBeckettLAToward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s diseaseAlzheimers Dement20117328029221514248
   PubMed Web of Science ®Google Scholar
• McKhannGMKnopmanDSChertkowHThe diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s diseaseAlzheimers Dement20117326326921514250
   PubMed Web of Science ®Google Scholar
• AlbertMSDeKoskySTDicksonDThe diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s diseaseAlzheimers Dement20117327027921514249
   PubMed Web of Science ®Google Scholar
• JackCRJrAlbertMSKnopmanDSIntroduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s diseaseAlzheimers Dement20117325726221514247
   PubMed Web of Science ®Google Scholar
• TengERingmanJMRossLKAlzheimer’s Disease Research Centers of California-Depression in Alzheimer’s Disease InvestigatorsDiagnosing depression in Alzheimer disease with the national institute of mental health provisional criteriaAm J Geriatr Psychiatry200816646947718515691
   PubMed Web of Science ®Google Scholar
• OlinJTSchneiderLSKatzIRProvisional diagnostic criteria for depression of Alzheimer diseaseAm J Geriatr Psychiatry200210212512811925273
   PubMed Web of Science ®Google Scholar
• KnopmanDSDeKoskySTCummingsJLPractice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of NeurologyNeurology20015691143115311342678
   PubMed Web of Science ®Google Scholar
• JagustWJBudingerTFReedBRThe diagnosis of dementia with single photon emission computed tomographyArch Neurol19874432582623493756
   PubMed Web of Science ®Google Scholar
• BirdJMLevyRJacobyRJComputed tomography in the elderly: changes over time in a normal populationBr J Psychiatry198614880853485462
   PubMed Web of Science ®Google Scholar
• LuxenbergJSHaxbyJVCreaseyHSundaramMRapoportSIRate of ventricular enlargement in dementia of the Alzheimer type correlates with rate of neuropsychological deteriorationNeurology1987377113511403496557
   PubMed Web of Science ®Google Scholar
• KillianyRJGomez-IslaTMossMUse of structural magnetic resonance imaging to predict who will get Alzheimer’s diseaseAnn Neurol200047443043910762153
   PubMed Web of Science ®Google Scholar
• KillianyRJHymanBTGomez-IslaTMRI measures of entorhinal cortex vs hippocampus in preclinical ADNeurology20025881188119611971085
   PubMed Web of Science ®Google Scholar
• MarshallGAMonserrattLHarwoodDMandelkernMCummingsJLSultzerDLPositron emission tomography metabolic correlates of apathy in Alzheimer diseaseArch Neurol20076471015102017620493
   PubMedGoogle Scholar
• MosconiLBertiVGlodzikLPupiADe SantiSde LeonMJPre-clinical detection of Alzheimer’s disease using FDG-PET, with or without amyloid imagingJ Alzheimers Dis201020384385420182025
   PubMed Web of Science ®Google Scholar
• MinoshimaSFreyKAKoeppeRAFosterNLKuhlDEA diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PETJ Nucl Med1995367123812487790950
   PubMed Web of Science ®Google Scholar
• EdisonPArcherHAHinzRAmyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET studyNeurology200768750150817065593
   PubMed Web of Science ®Google Scholar
• DukartJKherifFMuellerKAlzheimer’s Disease Neuroimaging InitiativeGenerative FDG-PET and MRI model of aging and disease progression in Alzheimer’s diseasePLoS Comput Biol201394e100298723592957
   PubMed Web of Science ®Google Scholar
• ChoiSRSchneiderJABennettDACorrelation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissueAlzheimer Dis Assoc Disord201226181622354138
   PubMed Web of Science ®Google Scholar
• ClarkCMSchneiderJABedellBJAV45-A07 Study GroupUse of florbetapir-PET for imaging beta-amyloid pathologyJAMA2011305327528321245183
   PubMed Web of Science ®Google Scholar
• Lister-JamesJPontecorvoMJClarkCFlorbetapir f-18: a histopathologically validated beta-amyloid positron emission tomography imaging agentSemin Nucl Med201141430030421624563
   PubMed Web of Science ®Google Scholar
• JohnsonKASperlingRAGidicsinCMAV45-A11 study groupFlorbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer’s disease dementia, mild cognitive impairment, and normal agingAlzheimers Dement201395 SupplS72S8323375563
   PubMedGoogle Scholar
• VandenbergheRVan LaereKIvanoiuA18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trialAnn Neurol201068331932920687209
   PubMed Web of Science ®Google Scholar
• HarveyRJSkelton-RobinsonMRossorMNThe prevalence and causes of dementia in people under the age of 65 yearsJ Neurol Neurosurg Psychiatry20037491206120912933919
   PubMed Web of Science ®Google Scholar
• OsimaniABergerAFriedmanJPorat-KatzBSAbarbanelJMNeuropsychology of vitamin B12 deficiency in elderly dementia patients and control subjectsJ Geriatr Psychiatry Neurol2005181333815681626
   PubMed Web of Science ®Google Scholar
• VargasAPCarod-ArtalFJDel NegroMCRodriguesMPDementia caused by neurosyphilis: clinical and neuropsychological follow-up of a patientArq Neuropsiquiatr2000582B578582 Portuguese10920426
   PubMed Web of Science ®Google Scholar
• FlemingKCAdamsACPetersenRCDementia: diagnosis and evaluationMayo Clin Proc19957011109311077475341
   PubMed Web of Science ®Google Scholar
• RasmussenKLTybjærg-HansenANordestgaardBGFrikke-SchmidtRApolipoprotein E plasma level and genotype – /INS; risk of dementia in 76,000 individuals from the general populationJ Neurol Sci2013333e342
   Google Scholar
• GoldmanJSHahnSECataniaJWAmerican College of Medical Genetics and the National Society of Genetic CounselorsGenetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic CounselorsGenet Med201113659760521577118
   PubMed Web of Science ®Google Scholar
• KulkarniPVRoneyCAAntichPPBonteFJRaghuAVAminabhaviTMQuinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer’s diseaseWiley Interdiscip Rev Nanomed Nanobiotechnol201021354720049829
   PubMed Web of Science ®Google Scholar
• HärtigWPaulkeBRVargaCSeegerJHarkanyTKaczaJElectron microscopic analysis of nanoparticles delivering thioflavin-T after intrahippocampal injection in mouse: implications for targeting beta-amyloid in Alzheimer’s diseaseNeurosci Lett2003338217417612566180
   PubMed Web of Science ®Google Scholar
• MassoudFLégerGCPharmacological treatment of Alzheimer diseaseCan J Psychiatry2011561057958822014690
   PubMed Web of Science ®Google Scholar
• WinslowBTOnyskoMKStobCMHazlewoodKATreatment of Alzheimer diseaseAm Fam Physician201183121403141221671540
   PubMed Web of Science ®Google Scholar
• BentleyPDriverJDolanRJModulation of fusiform cortex activity by cholinesterase inhibition predicts effects on subsequent memoryBrain2009132Pt 92356237119605530
   PubMedGoogle Scholar
• KavirajanHMemantine: a comprehensive review of safety and efficacyExpert Opin Drug Saf2009818910919236221
   PubMed Web of Science ®Google Scholar
• LiptonSAThe molecular basis of memantine action in Alzheimer’s disease and other neurologic disorders: low-affinity, uncompetitive antagonismCurr Alzheimer Res20052215516515974913
   PubMedGoogle Scholar
• MarkLPProstRWUlmerJLPictorial review of glutamate excitotoxicity: fundamental concepts for neuroimagingAJNR Am J Neuroradiol200122101813182411733308
   PubMed Web of Science ®Google Scholar
• MolinuevoJLLladóARamiLMemantine: targeting glutamate excitotoxicity in Alzheimer’s disease and other dementiasAm J Alzheimers Dis Other Demen2005202778515844753
   PubMedGoogle Scholar
• CacabelosRTakedaMWinbladBThe glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer’s diseaseInt J Geriatr Psychiatry199914134710029935
   PubMed Web of Science ®Google Scholar
• XiaPChenHSZhangDLiptonSAMemantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapsesJ Neurosci20103033112461125020720132
   PubMed Web of Science ®Google Scholar
• RammesGDanyszWParsonsCGPharmacodynamics of memantine: an updateCurr Neuropharmacol200861557819305788
   PubMed Web of Science ®Google Scholar
• ParsonsCGStöfflerADanyszWMemantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system – too little activation is bad, too much is even worseNeuropharmacology200753669972317904591
   PubMed Web of Science ®Google Scholar
• SrinivasanMLahiriDKSignificance of NF-κB as a pivotal therapeutic target in the neurodegenerative pathologies of Alzheimer’s disease and multiple sclerosisExpert Opin Ther Targets201519447148725652642
   PubMed Web of Science ®Google Scholar
• Rubio-PerezJMMorillas-RuizJMA review: inflammatory process in Alzheimer’s disease, role of cytokinesScientific World Journal2012201275635722566778
   PubMed Web of Science ®Google Scholar
• Wyss-CorayTRogersJInflammation in Alzheimer disease-a brief review of the basic science and clinical literatureCold Spring Harb Perspect Med201221a00634622315714
   PubMed Web of Science ®Google Scholar
• AlyautdinRKhalinINafeezaMIHaronMHKuznetsovDNanoscale drug delivery systems and the blood–brain barrierInt J Nanomedicine2014979581124550672
   PubMed Web of Science ®Google Scholar
• HaqueSMdSAlamMISahniJKAliJBabootaSNanostructure-based drug delivery systems for brain targetingDrug Dev Ind Pharm201238438741121954902
   PubMed Web of Science ®Google Scholar
• PaolinoDCoscoDMolinaroRCeliaCFrestaMSupramolecular devices to improve the treatment of brain diseasesDrug Discov Today2011167–831132421335100
   PubMed Web of Science ®Google Scholar
• AmidonGLLennernäsHShahVPCrisonJRA theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailabilityPharm Res19951234134207617530
   PubMed Web of Science ®Google Scholar
• StegemannSLeveillerFFranchiDde JongHLindénHWhen poor solubility becomes an issue: from early stage to proof of conceptEur J Pharm Sci200731524926117616376
   PubMed Web of Science ®Google Scholar
• OesterlingBMGulatiAJoshiMDNanocarrier-based approaches for treatment and detection of Alzheimer’s diseaseJ Nanosci Nanotechnol201414113715624730256
   PubMed Web of Science ®Google Scholar
• PatelMMGoyalBRBhadadaSVBhattJSAminAFGetting into the brain: approaches to enhance brain drug deliveryCNS Drugs2009231355819062774
   PubMed Web of Science ®Google Scholar
• SainsburyFZengBMiddelbergAPJTowards designer nanoemulsions for precision delivery of therapeuticsCurr Opin Chem Eng201441117
   Web of Science ®Google Scholar
• AprahamianMMichelCHumbertWDevissaguetJPDamgeCTransmucosal passage of polyalkylcyanoacrylate nanocapsules as a new drug carrier in the small intestineBiol Cell1987611–269762833966
   PubMed Web of Science ®Google Scholar
• GraffCLPollackGMNasal drug administration: potential for targeted central nervous system deliveryJ Pharm Sci20059461187119515858850
   PubMed Web of Science ®Google Scholar
• MathisonSNagillaRKompellaUBNasal route for direct delivery of solutes to the central nervous system: fact or fiction?J Drug Target1998564154419783675
   PubMed Web of Science ®Google Scholar
• KreuterJNanoparticles and nanocapsules – new dosage forms in the nanometer size rangePharm Acta Helv19785323339353818
   PubMedGoogle Scholar
• GuterresSSAlvesMPPohlmannARPolymeric nanoparticles, nanospheres and nanocapsules, for cutaneous applicationsDrug Target Insights2007214715721901071
   PubMedGoogle Scholar
• CouvreurPBarrattGFattalEVauthierCNanocapsule technology: a review200219236
   Google Scholar
• BoudadHLegrandPLebasGCheronMDuchêneDPonchelGCombined hydroxypropyl-beta-cyclodextrin and poly(alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavirInt J Pharm20012181–211312411337155
   PubMedGoogle Scholar
• SoutoEBSeverinoPSantanaMHAPreparação de nanopartículas poliméricas a partir da polimerização de monômeros: parte I [Preparation of polymeric nanoparticles by polymerization of monomers: part I]Polímeros20122296100 Portuguese
   Google Scholar
• DongYNgWKShenSKimSTanRBScalable ionic gelation synthesis of chitosan nanoparticles for drug delivery in static mixersCarbohydr Polym201394294094523544653
   PubMed Web of Science ®Google Scholar
• AroraSGuptaSNarangRKBudhirajaRDAmoxicillin loaded chitosan-alginate polyelectrolyte complex nanoparticles as mucopenetrating delivery system for H. pyloriSci Pharm201179367369421886911
   PubMedGoogle Scholar
• MainardesRMEvangelistaRCPraziquantel-loaded PLGA nanoparticles: preparation and characterizationJ Microencapsul2005221132416019887
   PubMed Web of Science ®Google Scholar
• MainardesRMEvangelistaRCPLGA nanoparticles containing praziquantel: effect of formulation variables on size distributionInt J Pharm20052901–213714415664139
   PubMed Web of Science ®Google Scholar
• AlshamsanANanoprecipitation is more efficient than emulsion solvent evaporation method to encapsulate cucurbitacin I in PLGA nanoparticlesSaudi Pharm J201422321922225061407
   PubMed Web of Science ®Google Scholar
• MainardesRMGremiãoMPDNanoencapsulation and characterization of zidovudine on poly(L-lactide) and poly(L-lactide)-poly(ethylene glycol)-blend nanoparticlesJ Nanosci Nanotechnol201212118513852123421238
   PubMed Web of Science ®Google Scholar
• CalvoPRemuñán-LópezCVila-JatoJLAlonsoMJNovel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriersJ Appl Polym Sci1997631125132
   Web of Science ®Google Scholar
• MurakamiHKobayashiMTakeuchiHKawashimaYPreparation of poly(dl-lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion methodInt J Pharm1999187214315210502620
   PubMed Web of Science ®Google Scholar
• MazzarinoLCoche-GuérenteLLabbéPLemos-SennaEBorsaliROn the mucoadhesive properties of chitosan-coated polycaprolactone nanoparticles loaded with curcumin using quartz crystal microbalance with dissipation monitoringJ Biomed Nanotechnol201410578779424734531
   PubMed Web of Science ®Google Scholar
• BilatiUAllémannEDoelkerEDevelopment of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticlesEur J Pharm Sci2005241677515626579
   PubMed Web of Science ®Google Scholar
• AliMELamprechtASpray freeze drying for dry powder inhalation of nanoparticlesEur J Pharm Biopharm201487351051724657824
   PubMed Web of Science ®Google Scholar
• HuXGuoYWangLHuaDHongYLiJCoenzyme Q10 nanoparticles prepared by a supercritical fluid-based methodJ Supercrit Fluids20115716672
   Web of Science ®Google Scholar
• ChuKSHasanWRawalSPlasma, tumor and tissue pharmacokinetics of Docetaxel delivered via nanoparticles of different sizes and shapes in mice bearing SKOV-3 human ovarian carcinoma xenograftNanomedicine20139568669323219874
   PubMed Web of Science ®Google Scholar
• GallowayALMurphyADeSimoneJMDevelopment of a nanoparticle-based influenza vaccine using the PRINT technologyNanomedicine20139452353123178283
   PubMed Web of Science ®Google Scholar
• GrattonSEPohlhausPDLeeJGuoJChoMJDesimoneJMNanofabricated particles for engineered drug therapies: a preliminary biodistribution study of PRINT nanoparticlesJ Control Release20071211–2101817643544
   PubMed Web of Science ®Google Scholar
• JainKKNanobiotechnology-based drug delivery to the central nervous systemNeurodegener Dis20074428729117627131
   PubMed Web of Science ®Google Scholar
• WohlfartSGelperinaSKreuterJTransport of drugs across the blood–brain barrier by nanoparticlesJ Control Release2012161226427321872624
   PubMed Web of Science ®Google Scholar
• BarbuEMolnàrETsibouklisJGóreckiDCThe potential for nanoparticle-based drug delivery to the brain: overcoming the blood–brain barrierExpert Opin Drug Deliv20096655356519435406
   PubMed Web of Science ®Google Scholar
• GaoKJiangXInfluence of particle size on transport of methotrexate across blood–brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticlesInt J Pharm20063101–221321916426779
   PubMedGoogle Scholar
• SoniSBabbarAKSharmaRKBanerjeeTMaitraAPharmacoscintigraphic evaluation of polysorbate 80-coated chitosan nanoparticles for brain targetingAmerican Journal of Drug Delivery200533205212
   Google Scholar
• JainKKNanoneurologyApplications of Biotechnology in NeurologyNew YorkHumana Press2013283294
   Google Scholar
• ZhangBSunXMeiHLDLR-mediated peptide-22-conjugated nanoparticles for dual-targeting therapy of brain gliomaBiomaterials201334369171918224008043
   PubMed Web of Science ®Google Scholar
• KuoYCHongTYDelivering etoposide to the brain using catanionic solid lipid nanoparticles with surface 5-HT-modulineInt J Pharm20144651–213214224524828
   PubMedGoogle Scholar
• ZensiABegleyDPontikisCAlbumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neuronesJ Control Release20091371788619285109
   PubMed Web of Science ®Google Scholar
• XinHShaXJiangXThe brain targeting mechanism of Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) nanoparticlesBiomaterials20123351673168122133551
   PubMed Web of Science ®Google Scholar
• LuWTanYZHuKLJiangXGCationic albumin conjugated pegylated nanoparticle with its transcytosis ability and little toxicity against blood–brain barrierInt J Pharm20052951–224726015848009
   PubMedGoogle Scholar
• MainardesRMUrbanMCCintoPOChaudMVEvangelistaRCGremiãoMPLiposomes and micro/nanoparticles as colloidal carriers for nasal drug deliveryCurr Drug Deliv20063327528516848729
   PubMedGoogle Scholar
• MistryAStolnikSIllumLNanoparticles for direct nose-to-brain delivery of drugsInt J Pharm2009379114615719555750
   PubMed Web of Science ®Google Scholar
• IllumLTransport of drugs from the nasal cavity to the central nervous systemEur J Pharm Sci200011111810913748
   PubMed Web of Science ®Google Scholar
• VilaAGillHMcCallionOAlonsoMaJTransport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating densityJ Control Release200498223124415262415
   PubMed Web of Science ®Google Scholar
• RochaSTargeted drug delivery across the blood–brain barrier in Alzheimer’s diseaseCurr Pharm Des201319376635664623621533
   PubMed Web of Science ®Google Scholar
• PawarDMangalSGoswamiRJaganathanKSDevelopment and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activityEur J Pharm Biopharm2013853 Pt A55055923831265
   PubMed Web of Science ®Google Scholar
• SunWXieCWangHHuYSpecific role of polysorbate 80 coating on the targeting of nanoparticles to the brainBiomaterials200425153065307114967540
   PubMed Web of Science ®Google Scholar
• GaoXTaoWLuWLectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administrationBiomaterials200627183482349016510178
   PubMed Web of Science ®Google Scholar
• GutzmannHHadlerDSustained efficacy and safety of idebenone in the treatment of Alzheimer’s disease: update on a 2-year double-blind multicentre studyJ Neural Transm Suppl1998543013109850939
   PubMedGoogle Scholar
• WeyerGBabej-DölleRMHadlerDHofmannSHerrmannWMA controlled study of 2 doses of idebenone in the treatment of Alzheimer’s diseaseNeuropsychobiology199736273829267856
   PubMed Web of Science ®Google Scholar
• SinhaMBhowmickPBanerjeeAChakrabartiSAntioxidant role of amyloid β protein in cell-free and biological systems: implication for the pathogenesis of Alzheimer diseaseFree Radic Biol Med20135618419223041348
   PubMed Web of Science ®Google Scholar
• ButterfieldDACastegnaALauderbackCMDrakeJEvidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer’s disease brain contribute to neuronal deathNeurobiol Aging200223565566412392766
   PubMed Web of Science ®Google Scholar
• ButterfieldDAYatinSMVaradarajanSKoppalTAmyloid beta-peptide-associated free radical oxidative stress, neurotoxicity, and Alzheimer’s diseaseMethods Enzymol199930974676810507060
   PubMed Web of Science ®Google Scholar
• IllumLChitosan and its use as a pharmaceutical excipientPharm Res1998159132613319755881
   PubMed Web of Science ®Google Scholar
• SmartJDThe basics and underlying mechanisms of mucoadhesionAdv Drug Deliv Rev200557111556156816198441
   PubMed Web of Science ®Google Scholar
• CarvalhoFCBruschiMLEvangelistaRCGremiãoMPDMucoadhesive drug delivery systemsBrazilian Journal of Pharmaceutical Sciences201046117
   Web of Science ®Google Scholar
• CarvalhoFCChorilliMGremiãoMPDPlataformas bio(muco) adesivas poliméricas baseadas em nanotecnologia para liberação controlada de fármacos – propriedades, metodologias e aplicaçõesPolímeros201424203213 Portuguese
   Google Scholar
• CardileVFrascaGRizzaLImproved adhesion to mucosal cells of water-soluble chitosan tetraalkylammonium saltsInt J Pharm20083621–2889218634863
   PubMedGoogle Scholar
• HenriksenIGreenKLSmartJDSmistadGKarlsenJBioadhesion of hydrated chitosans: an in vitro and in vivo studyInt J Pharm19961451–2231240
   Google Scholar
• BodmerMVankanPDreierMKutzKWDreweJPharmacokinetics and metabolism of idebenone in healthy male subjectsEur J Clin Pharmacol200965549350119125241
   PubMed Web of Science ®Google Scholar
• MüllerRHRadtkeMWissingSASolid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparationsAdv Drug Deliv Rev200254Suppl 1S131S15512460720
   PubMed Web of Science ®Google Scholar
• MehnertWMäderKSolid lipid nanoparticles: production, characterization and applicationsAdv Drug Deliv Rev201264Suppl83101
   Web of Science ®Google Scholar
• PardeikeJHommossAMüllerRHLipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal productsInt J Pharm20093661–217018418992314
   PubMed Web of Science ®Google Scholar
• KovačevićABMüllerRHSavićSDVuletaGMKeckCMSolid lipid nanoparticles (SLN) stabilized with polyhydroxy surfactants: preparation, characterization and physical stability investigationColloids Surf A Physicochem Eng Asp20144441525
   Web of Science ®Google Scholar
• LukowskiGKasbohmJPflegelPIllingAWulffHCrystallographic investigation of cetylpalmitate solid lipid nanoparticlesInt J Pharm2000196220120510699718
   PubMedGoogle Scholar
• MartinsSMSarmentoBNunesCLúcioMReisSFerreiraDCBrain targeting effect of camptothecin-loaded solid lipid nanoparticles in rat after intravenous administrationEur J Pharm Biopharm2013853 Pt A48850223994244
   PubMed Web of Science ®Google Scholar
• XieSZhuLDongZPreparation, characterization and pharmacokinetics of enrofloxacin-loaded solid lipid nanoparticles: influences of fatty acidsColloids Surf B Biointerfaces201183238238721215599
   PubMed Web of Science ®Google Scholar
• Kolenyak-SantosFGarneroCOliveiraRNNanostructured lipid carriers as a strategy to improve the in vitro schistosomiasis activity of praziquantelJ Nanosci Nanotechnol20141411224730249
   PubMedGoogle Scholar
• KumarVVChandrasekarDRamakrishnaSKishanVRaoYMDiwanPVDevelopment and evaluation of nitrendipine loaded solid lipid nanoparticles: Influence of wax and glyceride lipids on plasma pharmacokineticsInt J Pharm20073351–216717517161566
   PubMed Web of Science ®Google Scholar
• DasSNgWKKanaujiaPKimSTanRBFormulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variablesColloids Surf B Biointerfaces201188148348921831615
   PubMed Web of Science ®Google Scholar
• VitorinoCCarvalhoFAAlmeidaAJSousaJJPaisAAThe size of solid lipid nanoparticles: an interpretation from experimental designColloids Surf B Biointerfaces201184111713021242064
   PubMed Web of Science ®Google Scholar
• RahmanZZidanASKhanMANon-destructive methods of characterization of risperidone solid lipid nanoparticlesEur J Pharm Biopharm201076112713720470882
   PubMed Web of Science ®Google Scholar
• KumarRYasirMSarafSAGaurPKKumarYSinghAPGlyceryl monostearate based nanoparticles of mefenamic acid: fabrication and in vitro characterizationDrug Invention Today201353246250
   Google Scholar
• YasirMSaraUVSPreparation and optimization of haloperidol loaded solid lipid nanoparticles by Box–Behnken designJ Pharm Res201376551558
   Google Scholar
• SinghAPSarafSKSarafSSLN approach for nose-to-brain delivery of alprazolamDrug Deliv Transl Res20122649850725787328
   PubMed Web of Science ®Google Scholar
• TrottaMDebernardiFCaputoOPreparation of solid lipid nanoparticles by a solvent emulsification-diffusion techniqueInt J Pharm20032571–215316012711170
   PubMed Web of Science ®Google Scholar
• CampardelliRCherainMPerfettiCLipid nanoparticles production by supercritical fluid assisted emulsion–diffusionJ Supercrit Fluids2013823440
   Web of Science ®Google Scholar
• Acevedo-MorantesCYAcevedo-MorantesMTSuleiman-RosadoDRamírez-VickJEEvaluation of the cytotoxic effect of camptothecin solid lipid nanoparticles on MCF7 cellsDrug Deliv201320833834824024505
   PubMed Web of Science ®Google Scholar
• de SouzaALRAndreaniTNunesFMLoading of praziquantel in the crystal lattice of solid lipid nanoparticlesJ Therm Anal Calorim20121081353360
   Web of Science ®Google Scholar
• de SouzaALRAndreaniTde OliveiraRNIn vitro evaluation of permeation, toxicity and effect of praziquantel-loaded solid lipid nanoparticles against Schistosoma mansoni as a strategy to improve efficacy of the schistosomiasis treatmentInt J Pharm20144631313724370839
   PubMedGoogle Scholar
• de AlmeidaAESouzaALRCassimiroDLGremiãoMPDRibeiroCACrespiMSThermal characterization of solid lipid nanoparticles containing praziquantelJ Therm Anal Calorim20121081333339
   Web of Science ®Google Scholar
• FreitasCMülleraRHSpray-drying of solid lipid nanoparticles (SLN TM)Eur J Pharm Biopharm19984621451519795036
   PubMed Web of Science ®Google Scholar
• BourezgZBourgeoisSPressendaSShehadaTFessiHRedispersible lipid nanoparticles of spironolactone obtained by three drying methodsColloids Surf A Physicochem Eng Asp2012413191199
   Web of Science ®Google Scholar
• ChavanSSIngleSGVaviaPRPreparation and characterization of solid lipid nanoparticle-based nasal spray of budesonideDrug Deliv Transl Res20133540240825788348
   PubMed Web of Science ®Google Scholar
• MartinsSSilvaACFerreiraDCSoutoEBImproving oral absorption of salmon calcitonin by trimyristin lipid nanoparticlesJ Biomed Nanotechnol200951768320055109
   PubMed Web of Science ®Google Scholar
• DongYNgWKShenSKimSTanRBSolid lipid nanoparticles: continuous and potential large-scale nanoprecipitation production in static mixersColloids Surf B Biointerfaces201294687222326649
   PubMed Web of Science ®Google Scholar
• HombachJBernkop-SchnürchAMucoadhesive drug delivery systemsHandb Exp Pharmacol201019725126620217533
   PubMedGoogle Scholar
• MasseriniMNanoparticles for brain drug deliveryISRN Biochem2013201323842825937958
   PubMedGoogle Scholar
• AlyautdinRNTezikovEBRamgePKharkevichDABegleyDJKreuterJSignificant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion studyJ Microencapsul199815167749463808
   PubMed Web of Science ®Google Scholar
• GulyaevAEGelperinaSESkidanINAntropovASKivmanGYKreuterJSignificant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticlesPharm Res199916101564156910554098
   PubMed Web of Science ®Google Scholar
• KreuterJAlyautdinRNKharkevichDAIvanovAAPassage of peptides through the blood–brain barrier with colloidal polymer particles (nanoparticles)Brain Res199567411711747773690
   PubMed Web of Science ®Google Scholar
• ThalLJSalmonDPLaskerBBowerDKlauberMRThe safety and lack of efficacy of vinpocetine in Alzheimer’s diseaseJ Am Geriatr Soc19893765155202715559
   PubMed Web of Science ®Google Scholar
• SzatmariSZWhitehousePJVinpocetine for cognitive impairment and dementiaCochrane Database Syst Rev20031CD00311912535455
   PubMedGoogle Scholar
• MarambaudPVingtdeuxVGilibertoLResveratrol lowers beta-amyloid accumulation and deposition in vivo by controlling AMPK signalingAlzheimers Dement201064S406
   Google Scholar
• BondiMLMontanaGCraparoEFFerulic acid-loaded lipid nanostructures as drug delivery systems for Alzheimer’s disease: preparation, characterization and cytotoxicity studiesCurr Nanosci2009512632
   Web of Science ®Google Scholar
• WangBSWangHWeiZHSongYYZhangLChenHZEfficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer’s disease: an updated meta-analysisJ Neural Transm2009116445746519221692
   PubMed Web of Science ®Google Scholar
• HuangHCChangPDaiXLJiangZFProtective effects of curcumin on amyloid-β-induced neuronal oxidative damageNeurochem Res20123771584159722476982
   PubMed Web of Science ®Google Scholar
• OnoKHasegawaKNaikiHYamadaMCurcumin has potent anti-amyloidogenic effects for Alzheimer’s beta-amyloid fibrils in vitroJ Neurosci Res200475674275014994335
   PubMed Web of Science ®Google Scholar
• YangFLimGPBegumANCurcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivoJ Biol Chem200528075892590115590663
   PubMed Web of Science ®Google Scholar
• ZhaoLNChiuSWBenoitJChewLYMuYThe effect of curcumin on the stability of Aβ dimersJ Phys Chem B2012116257428743522690789
   PubMed Web of Science ®Google Scholar
• WangWZhuRXieQEnhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticlesInt J Nanomedicine201273667367722888226
   PubMed Web of Science ®Google Scholar
• SunJBiCChanHMSunSZhangQZhengYCurcumin-loaded solid lipid nanoparticles have prolonged in vitro antitumour activity, cellular uptake and improved in vivo bioavailabilityColloids Surf B Biointerfaces201311136737523856543
   PubMed Web of Science ®Google Scholar
• WangPZhangLPengHLiYXiongJXuZThe formulation and delivery of curcumin with solid lipid nanoparticles for the treatment of on non-small cell lung cancer both in vitro and in vivoMater Sci Eng C Mater Biol Appl20133384802480824094190
   PubMed Web of Science ®Google Scholar
• VanditaKShashiBSantoshKGPalKIEnhanced apoptotic effect of curcumin loaded solid lipid nanoparticlesMol Pharm20129123411342123127155
   PubMedGoogle Scholar
• GuriAGülserenICorredigMUtilization of solid lipid nanoparticles for enhanced delivery of curcumin in cocultures of HT29-MTX and Caco-2 cellsFood Funct2013491410141923921424
   PubMed Web of Science ®Google Scholar
• JiHTangJLiMRenJZhengNWuLCurcumin-loaded solid lipid nanoparticles with Brij78 and TPGS improved in vivo oral bio-availability and in situ intestinal absorption of curcumin. Drug DelivEpub201463112
   Google Scholar
• AlexAPaulWChackoAJSharmaCPEnhanced delivery of lopinavir to the CNS using Compritol-based solid lipid nanoparticlesTher Deliv201121253522833923
   PubMedGoogle Scholar
• KuoYCLiangCTInhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptorBiomaterials201132123340335021296415
   PubMed Web of Science ®Google Scholar
• MartinsSThoIReimoldIBrain delivery of camptothecin by means of solid lipid nanoparticles: formulation design, in vitro and in vivo studiesInt J Pharm20124391–2496223046667
   PubMedGoogle Scholar
• WangJXSunXZhangZREnhanced brain targeting by synthesis of 3′,5′-dioctanoyl-5-fluoro-2′-deoxyuridine and incorporation into solid lipid nanoparticlesEur J Pharm Biopharm200254328529012445558
   PubMed Web of Science ®Google Scholar
• LasicDDNovel applications of liposomesTrends Biotechnol19981673073219675915
   PubMed Web of Science ®Google Scholar
• GulatiMGroverMSinghSSinghMLipophilic drug derivatives in liposomesInt J Pharm19981652129168
   Web of Science ®Google Scholar
• XuXKhanMABurgessDJPredicting hydrophilic drug encapsulation inside unilamellar liposomesInt J Pharm2012423241041822207162
   PubMedGoogle Scholar
• GhanbarzadehSValizadehHZakeri-MilaniPApplication of response surface methodology in development of sirolimus liposomes prepared by thin film hydration techniqueBioimpacts201332758123878790
   PubMedGoogle Scholar
• ElzainyAAGuXSimonsFESimonsKJHydroxyzine- and cetirizine-loaded liposomes: effect of duration of thin film hydration, freeze-thawing, and changing buffer pH on encapsulation and stabilityDrug Dev Ind Pharm200531328129115830724
   PubMed Web of Science ®Google Scholar
• LiXChenDLeCNovel mucus-penetrating liposomes as a potential oral drug delivery system: preparation, in vitro char-acterization, and enhanced cellular uptakeInt J Nanomedicine201163151316222163166
   PubMed Web of Science ®Google Scholar
• ChorilliMCalixtoGRimérioTCScarpaMVCaffeine encapsulated in small unilamellar liposomes: characerization and in vitro release profileJ Dispers Sci Technol2013341014651470
   Web of Science ®Google Scholar
• ChorilliMRimérioTCDe OliveiraAGScarpaMVStudy of liposomes stability containing soy phosphatidylcholine and hydrogenated soy phosphatydylcholine adding or not cholesterol by turbidity methodLatin American Journal of Pharmacy20072613137
   Web of Science ®Google Scholar
• ChorilliMRimérioTCDe OliveiraAGScarpaMVObtaining and characterization of small unilamellar liposomes containing caffeineLatin American Journal of Pharmacy2007265715722
   Web of Science ®Google Scholar
• BarichelloJMKizukiSTagamiTAgitation during lipoplex formation harmonizes the interaction of siRNA to cationic liposomesInt J Pharm20124301–235936522525078
   PubMedGoogle Scholar
• HadianZSahariMAMoghimiHRBarzegarMFormulation, characterization and optimization of liposomes containing eicosapentaenoic and docosahexaenoic acids; a methodology approachIran J Pharm Res201413239340425237335
   PubMed Web of Science ®Google Scholar
• ChoNJHwangLYSolandtJJRFrankCWComparison of extruded and sonicated vesicles for planar bilayer self-assemblyMaterials20136832943308
   PubMed Web of Science ®Google Scholar
• IsailovićBDKostićITZvonarAResveratrol loaded liposomes produced by different techniquesInnovative Food Science and Emerging Technologies201319181189
   Web of Science ®Google Scholar
• CurićAReulRMöschwitzerJFrickerGFormulation optimization of itraconazole loaded PEGylated liposomes for parenteral administration by using design of experimentsInt J Pharm2013448118919723524086
   PubMed Web of Science ®Google Scholar
• NinomiyaKKawabataSTashitaHShimizuNUltrasound-mediated drug delivery using liposomes modified with a thermosensitive polymerUltrason Sonochem201421131031623948493
   PubMed Web of Science ®Google Scholar
• MourãoSCCostaPISalgadoHRGremiãoMPImprovement of antischistosomal activity of praziquantel by incorporation into phosphatidylcholine-containing liposomesInt J Pharm20052951–215716215848000
   PubMedGoogle Scholar
• YePZhangWYangTFolate receptor-targeted liposomes enhanced the antitumor potency of imatinib through the combination of active targeting and molecular targetingInt J Nanomedicine201492167217824855354
   PubMed Web of Science ®Google Scholar
• OlsonFHuntCASzokaFCVailWJPapahadjopoulosDPreparation of liposomes of defined size distribution by extrusion through polycarbonate membranesBiochim Biophys Acta1979557192395096
   PubMed Web of Science ®Google Scholar
• JousmaHTalsmaHSpiesFJoostenJGHJungingerHECrommelinDJACharacterization of liposomes. The influence of extrusion of multilamellar vesicles through polycarbonate membranes on particle size, particle size distribution and number of bilayersInt J Pharm1987353263274
   Google Scholar
• BergerNSachseABenderJSchubertRBrandlMFilter extrusion of liposomes using different devices: comparison of liposome size, encapsulation efficiency, and process characteristicsInt J Pharm20012231–2556811451632
   PubMed Web of Science ®Google Scholar
• PupoEPadrónASantanaEPreparation of plasmid DNA-containing liposomes using a high-pressure homogenization – extrusion techniqueJ Control Release2005104237939615907587
   PubMed Web of Science ®Google Scholar
• Barnadas-RodríguezRSabésMFactors involved in the production of liposomes with a high-pressure homogenizerInt J Pharm20012131–217518611165105
   PubMed Web of Science ®Google Scholar
• BrandlMBachmannDDrechslerMBauerKHLiposome preparation by a new high pressure homogenizer Gaulin Micron Lab 40Drug Dev Ind Pharm1990161421672191
   Web of Science ®Google Scholar
• ChungSKShinGHJungMKHwangICParkHJFactors influencing the physicochemical characteristics of cationic polymer-coated liposomes prepared by high-pressure homogenizationColloids Surf A Physicochem Eng Asp2014454815
   Web of Science ®Google Scholar
• SzokaFJrPapahadjopoulosDProcedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporationProc Natl Acad Sci U S A197875941944198279908
   PubMed Web of Science ®Google Scholar
• CortesiREspositoEGambarinSTelloliPMenegattiENastruzziCPreparation of liposomes by reverse-phase evaporation using alternative organic solventsJ Microencapsul199916225125610080118
   PubMed Web of Science ®Google Scholar
• ChenGLiDJinYDeformable liposomes by reverse-phase evaporation method for an enhanced skin delivery of (+)-catechinDrug Dev Ind Pharm201340226026523356860
   PubMed Web of Science ®Google Scholar
• García-JimenoSEscribanoEQueraltJEstelrichJMagnetoliposomes prepared by reverse-phase followed by sequential extrusion: Characterization and possibilities in the treatment of inflammationInt J Pharm20114051–218118721129463
   PubMedGoogle Scholar
• KaurIPGargASinglaAKAggarwalDVesicular systems in ocular drug delivery: an overviewInt J Pharm2004269111414698571
   PubMed Web of Science ®Google Scholar
• MalmstenMLiposomesSurfactants and Polymers in Drug DeliveryCRC Press2002
   Google Scholar
• AgarwalRKatareOPVyasSPPreparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranolInt J Pharm20012281–2435211576767
   PubMed Web of Science ®Google Scholar
• CevcGBlumeGLipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration forceBiochim Biophy Acta199211041226232
   PubMed Web of Science ®Google Scholar
• AroraSLambaHSTiwariRDermal delivery of drugs using different vesicular carriers: a comparative reviewAsian Journal of Pharmaceutics201264237244
   Google Scholar
• TouitouEDayanNBergelsonLGodinBEliazMEthosomes – novel vesicular carriers for enhanced delivery: characterization and skin penetration propertiesJ Control Release200065340341810699298
   PubMed Web of Science ®Google Scholar
• SarojSBabyDASabithaMCurrent trends in lipid based delivery systems and its applications in drug deliveryAsian Journal of Pharmaceutical and Clinical Research20125Suppl 349
   Google Scholar
• SchnyderAHuwylerJDrug transport to brain with targeted lipo-somesNeuro Rx20052199107
   Google Scholar
• De RosaGSalzanoGCaragliaMAbbruzzeseANanotechnologies: a strategy to overcome blood–brain barrierCurr Drug Metab2012131616922292810
   PubMed Web of Science ®Google Scholar
• LoureiroJAGomesBCoelhoMANdo Carmo PereiraMRochaSTargeting nanoparticles across the blood–brain barrier with monoclonal antibodiesNanomedicine (Lond)20149570972224827845
   PubMed Web of Science ®Google Scholar
• MuruganKChoonaraYEKumarPBijukumarDdu ToitLCPillayVParameters and characteristics governing cellular internalization and trans-barrier trafficking of nanostructuresInt J Nanomedicine2015102191220625834433
   PubMed Web of Science ®Google Scholar
• HerdaLMPoloEKellyPMRocksLHudeczDDawsonKADesigning the future of nanomedicine: current barriers to targeted brain therapeuticsEur J Nanomed201463127139
   Google Scholar
• LaiFFaddaAMSinicoCLiposomes for brain deliveryExpert Opin Drug Deliv20131071003102223373728
   PubMed Web of Science ®Google Scholar
• SalvatiEReFSesanaSLiposomes functionalized to overcome the blood–brain barrier and to target amyloid-β peptide: the chemical design affects the permeability across an in vitro modelInt J Nanomedicine201381749175823674890
   PubMed Web of Science ®Google Scholar
• HashizumeRFreyWHIIIntranasal delivery – a new therapeutic approach for brain tumorsUS Neurol2008424344
   Google Scholar
• TayebatiSKNwankwoIEAmentaFIntranasal drug delivery to the central nervous system: present status and future outlookCurr Pharm Des201319351052623116337
   PubMed Web of Science ®Google Scholar
• ShahLYadavSAmijiMNanotechnology for CNS delivery of bio-therapeutic agentsDrug Deliv Transl Res20133433635123894728
   PubMed Web of Science ®Google Scholar
• MaloufRGrimley EvansJFolic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented peopleCochrane Database Syst Rev20084CD00451418843658
   PubMed Web of Science ®Google Scholar
• BirksJGrimley EvansJGinkgo biloba for cognitive impairment and dementiaCochrane Database Syst Rev20091CD00312019160216
   PubMed Web of Science ®Google Scholar
• EzrahiSAserinAGartiNAggregation behavior in one-phase (Winsor IV) microemulsion systemsKumarPMittalKLHandbook of Microemulsion Science and TechnologyNew YorkMarcel Dekker, Inc1999195240
   Google Scholar
• MalmstenMSurfactants and Polymers in Drug DeliveryNew YorkCRC Press2002
   Google Scholar
• LangevinDMicroemulsionsAcc Chem Res1988217255260
   Web of Science ®Google Scholar
• ManoharanCBasarkarASinghJVarious pharmaceutical disperse systemsKulshreshthaAKSinghONWallGMPharmaceutical Suspensions: From Formulation Development to ManufacturingNew YorkSpringer2010137
   Google Scholar
• McClementsDJNanoemulsions versus microemulsions: terminology, differences, and similaritiesSoft Matter20128617191729
   Web of Science ®Google Scholar
• MasonTGWilkingJNMelesonKChangCBGravesSMNanoemulsions: formation, structure, and physical propertiesJ Phys Condens Matter200618R635
   Web of Science ®Google Scholar
• UrbanMCCMainardesRMGremiãoMPDDevelopment and validation of HPLC method for analysis of dexamethasone acetate in microemulsionsBrazilian Journal of Pharmaceutical Sciences2009458792
   Web of Science ®Google Scholar
• CarvalhoFCBarbiMdSGremiãoMPDLC evaluation of in vitro release of AZT from microemulsionsChromatographia2009692207211
   Google Scholar
• CarvalhoFCSarmentoVHChiavacciLABarbiMSGremiãoMPDevelopment and in vitro evaluation of surfactant systems for controlled release of zidovudineJ Pharm Sci20109952367237419967779
   PubMed Web of Science ®Google Scholar
• MacedoASQuelhasSSilvaAMSoutoEBNanoemulsions for delivery of flavonoids: formulation and in vitro release of rutin as model drugPharm Dev Technol201419667768023930932
   PubMed Web of Science ®Google Scholar
• DiasDdOColomboMKelmannRGOptimization of Copaiba oil-based nanoemulsions obtained by different preparation methodsInd Crops Prod201459154162
   Web of Science ®Google Scholar
• LeeLHancocksRNobleINortonITProduction of water-in-oil nanoemulsions using high pressure homogenisation: a study on droplet break-upJ Food Eng20141313337
   Web of Science ®Google Scholar
• JoYJKwonYJCharacterization of β-carotene nanoemulsions prepared by microfluidization techniqueFood Sci Biotechnol2014231107113
   Web of Science ®Google Scholar
• da SilvaGBScarpaMVRossaneziGdo EgitoESde OliveiraAGDevelopment and characterization of biocompatible isotropic and anisotropic oil-in-water colloidal dispersions as a new delivery system for methyl dihydrojasmonate antitumor drugInt J Nanomedicine2014986787624596463
   PubMed Web of Science ®Google Scholar
• SoodSJainKGowthamarajanKDelivery of neuroprotective polyphenol to the brain via an intranasal route for management of Alzheimer’s diseaseAlzheimers Dement201394P299
   Google Scholar
• ShiJCongWWangYLiuQLuoGMicroemulsion-based patch for transdermal delivery of huperzine A and ligustrazine phosphate in treatment of Alzheimer’s diseaseDrug Dev Ind Pharm201238675276122014311
   PubMed Web of Science ®Google Scholar
• MalmstenMLiquid crystalsSurfactants and Polymers in Drug DeliveryCRC Press2002
   Google Scholar
• KatoTLiquid Crystalline Functional Assemblies and Their Supramolecular StructuresNew YorkSpringer2008
   Google Scholar
• Mueller-GoymannCCFrankSGInteraction of lidocaine and lidocaine-HCl with the liquid crystal structure of topical preparationsInt J Pharm1986292–3147159
   Google Scholar
• MalmstenMPhase transformations in self-assembly systems for drug delivery applicationsJ Dispers Sci Technol20072816372
   Web of Science ®Google Scholar
• GartiNLibsterDAserinALipid polymorphism in lyotropic liquid crystals for triggered release of bioactivesFood Funct20123770071322592749
   PubMed Web of Science ®Google Scholar
• KaasgaardTDrummondCJOrdered 2-D and 3-D nanostructured amphiphile self-assembly materials stable in excess solventPhys Chem Chem Phys20068434957497517091149
   PubMed Web of Science ®Google Scholar
• DrummondCJFongCSurfactant self-assembly objects as novel drug delivery vehiclesCurr Opin Colloid Interface Sci199946449456
   Web of Science ®Google Scholar
• YaghmurAGlatterOCharacterization and potential applications of nanostructured aqueous dispersionsAdv Colloid Interface Sci2009147–148333342
   PubMed Web of Science ®Google Scholar
• CarvalhoFCCamposMLPeccininiRGGremiãoMPDNasal administration of liquid crystal precursor mucoadhesive vehicle as an alternative antiretroviral therapyEur J Pharm Biopharm201384121922723207328
   PubMed Web of Science ®Google Scholar
• CarvalhoFCBarbiMSSarmentoVHChiavacciLANettoFMGremiãoMPSurfactant systems for nasal zidovudine delivery: structural, rheological and mucoadhesive propertiesJ Pharm Pharmacol201062443043920604831
   PubMed Web of Science ®Google Scholar
• ShahJCSadhaleYChilukuriDMCubic phase gels as drug delivery systemsAdv Drug Deliv Rev2001472–322925011311994
   PubMed Web of Science ®Google Scholar
• NielsenLSSchubertLHansenJBioadhesive drug delivery systems. I. Characterisation of mucoadhesive properties of systems based on glyceryl monooleate and glyceryl monolinoleateEur J Pharm Sci1998632312399795071
   PubMed Web of Science ®Google Scholar
• BruschiMLde FreitasOLaraEHPanzeriHGremiãoMPJonesDSPrecursor system of liquid crystalline phase containing propolis microparticles for the treatment of periodontal disease: development and characterizationDrug Dev Ind Pharm200834326727818363142
   PubMed Web of Science ®Google Scholar
• SpicerPTSmallWBIISmallWBLynchMLBurnsJLDry powder precursors of cubic liquid crystalline nanoparticles (cubosomes)J Nanopart Res200244297311
   Web of Science ®Google Scholar
• RenXSvirskisDAlanyRGZargar-ShoshtariSWuZIn-situ phase transition from microemulsion to liquid crystal with the potential of prolonged parenteral drug deliveryInt J Pharm20124311–213013722548845
   PubMed Web of Science ®Google Scholar
• ChanJMaghrabyGMCraigJPAlanyRGPhase transition water-in-oil microemulsions as ocular drug delivery systems: in vitro and in vivo evaluationInt J Pharm20073281657117092668
   PubMedGoogle Scholar
• AhmadMZAhmadJAminSRole of nanomedicines in delivery of anti-acetylcholinesterase compounds to the brain in Alzheimer’s diseaseCNS Neurol Disord Drug Targets20141381315132425345516
   PubMed Web of Science ®Google Scholar
• KumarNKumarRNanomedicine for neurological disordersNanotechnology and Nanomaterials in the Treatment of Life-Threatening DiseasesOxfordWilliam Andrew Publishing2014109175
   Google Scholar
• MiyakeMMBleierBSThe blood–brain barrier and nasal drug delivery to the central nervous systemAm J Rhinol Allergy201529212412725785753
   PubMed Web of Science ®Google Scholar
• WongYCZuoZIntranasal delivery – modification of drug metabolism and brain dispositionPharm Res20102771208122320372990
   PubMed Web of Science ®Google Scholar
• LigadePCJadhavKRKadamVJBrain drug delivery system: an overviewCurr Drug ther201052105110
   Google Scholar
• PathanSAIqbalZZaidiSMCNS drug delivery systems: novel approachesRecent Pat Drug Deliv Formul200931718919149731
   PubMedGoogle Scholar
• MittalDAliAMdSBabootaSSahniJKAliJInsights into direct nose to brain delivery: current status and future perspectiveDrug Deliv2014212758624102636
   PubMed Web of Science ®Google Scholar
• KozlovskayaLAbou-KaoudMStepenskyDQuantitative analysis of drug delivery to the brain via nasal routeJ Control Release201418913314024997277
   PubMed Web of Science ®Google Scholar
• AlamMIBegSSamadAStrategy for effective brain drug deliveryEur J Pharm Sci201040538540320497904
   PubMed Web of Science ®Google Scholar
• LajoieJMShustaEVTargeting receptor-mediated transport for delivery of biologics across the blood-brain barrierAnnu Rev Pharmacol Toxicol20155561363125340933
   PubMed Web of Science ®Google Scholar
• GaillardPJVisserCCAppeldoornCCRipJTargeted blood-to-brain drug deliver – 10 key development criteriaCurr Pharm Biotechnol201213122328233923016639
   PubMed Web of Science ®Google Scholar
• KozlovskayaLStepenskyDQuantitative analysis of the brain-targeted delivery of drugs and model compounds using nano-delivery systemsJ Control Release20131711172323831053
   PubMed Web of Science ®Google Scholar
• GulatiMChopraDSSinghSKSalujaVPathakPBansalPPatents on brain permeable nanoparticlesRecent Pat CNS Drug Discov20138322023424286450
   PubMedGoogle Scholar
• SpuchCSaidaONavarroCAdvances in the treatment of neurode-generative disorders employing nanoparticlesRecent Pat Drug Deliv Formul20126121822272933
   PubMedGoogle Scholar
• FanAMAlexeeffGNanotechnology and nanomaterials: toxicology, risk assessment, and regulationsJ Nanosci Nanotechnol201010128646865721121378
   PubMed Web of Science ®Google Scholar